171 related articles for article (PubMed ID: 21808135)
1. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma.
Das SN; Khare P; Singh MK; Sharma SC
Indian J Med Res; 2011 Jul; 134(1):54-60. PubMed ID: 21808135
[TBL] [Abstract][Full Text] [Related]
2. Correlation of cyclin D1 expression with aggressive DNA pattern in patients with tobacco-related intraoral squamous cell carcinoma.
Das SN; Khare P; Singh MK; Sharma SC
Indian J Med Res; 2011 Apr; 133(4):381-6. PubMed ID: 21537090
[TBL] [Abstract][Full Text] [Related]
3. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
[TBL] [Abstract][Full Text] [Related]
4. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity.
de Carvalho-Neto PB; dos Santos M; de Carvalho MB; Mercante AM; dos Santos VP; Severino P; Tajara EH; Louro ID; da Silva-Conforti AM
PLoS One; 2013; 8(7):e69024. PubMed ID: 23894399
[TBL] [Abstract][Full Text] [Related]
5. Effects of FasL expression in oral squamous cell cancer.
Fang L; Sun L; Hu FF; Chen QE
Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
[TBL] [Abstract][Full Text] [Related]
6. Expression of fas (CD95) ligand is correlated with IL-10 and granulocyte colony-stimulating factor expression in oral and oropharyngeal squamous cell carcinoma.
Fujieda S; Sunaga H; Tsuzuki H; Fan GK; Ito T; Sugimoto C; Saito H
Cancer Lett; 2000 Dec; 161(1):73-81. PubMed ID: 11078915
[TBL] [Abstract][Full Text] [Related]
7. Expression of ADAM10, Fas, FasL and Soluble FasL in Patients with Oral Squamous Cell Carcinoma (OSCC) and their Association with Clinical-Pathological Parameters.
Zepeda-Nuño JS; Guerrero-Velázquez C; Del Toro-Arreola S; Vega-Magaña N; Ángeles-Sánchez J; Haramati J; Pereira-Suárez AL; Bueno-Topete MR
Pathol Oncol Res; 2017 Apr; 23(2):345-353. PubMed ID: 27628319
[TBL] [Abstract][Full Text] [Related]
8. Association of DNA pattern of metastatic lymph node with disease free survival in patients with intraoral squamous cell carcinoma.
Das SN; Khare P; Patil A; Pandey RM; Singh MK; Shukla NK
Indian J Med Res; 2005 Sep; 122(3):216-23. PubMed ID: 16251778
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis.
Chen Q; Samaranayake LP; Zhen X; Luo G; Nie M; Li B
Oral Oncol; 1999 Nov; 35(6):548-53. PubMed ID: 10705088
[TBL] [Abstract][Full Text] [Related]
10. Expression of Fas/FasL in patients with oral lichen planus.
Hadzi-Mihailovic M; Raybaud H; Monteil R; Jankovic L
J BUON; 2009; 14(3):487-93. PubMed ID: 19810143
[TBL] [Abstract][Full Text] [Related]
11. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications.
Korkolopoulou P; Saetta AA; Levidou G; Gigelou F; Lazaris A; Thymara I; Scliri M; Bousboukea K; Michalopoulos NV; Apostolikas N; Konstantinidou A; Tzivras M; Patsouris E
Histopathology; 2007 Aug; 51(2):150-6. PubMed ID: 17559541
[TBL] [Abstract][Full Text] [Related]
12. [Expression and significance of Fas and FasL protein in squamous cell carcinoma of larynx].
Shi L; Li G; Zhu C
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Dec; 16(12):661-2. PubMed ID: 12669436
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer.
Shibakita M; Tachibana M; Dhar DK; Kotoh T; Kinugasa S; Kubota H; Masunaga R; Nagasue N
Clin Cancer Res; 1999 Sep; 5(9):2464-9. PubMed ID: 10499620
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of Fas (APO-1/CD95) ligand in human colorectal cancer.
Sheehan KM; O'Donovan DG; Fitzmaurice G; O'Grady A; O'Donoghue DP; Sheahan K; Byrne MF; Conroy RM; Kay EW; Murray FE
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):375-80. PubMed ID: 12655257
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.
Li Q; Peng J; Li XH; Liu T; Liang QC; Zhang GY
World J Gastroenterol; 2010 Mar; 16(10):1274-8. PubMed ID: 20222173
[TBL] [Abstract][Full Text] [Related]
16. FAS ligand expression in inflammatory infiltrate lymphoid cells as a prognostic marker in oral squamous cell carcinoma.
Peterle GT; Santos M; Mendes SO; Carvalho-Neto PB; Maia LL; Stur E; Agostini LP; Silva CV; Trivilin LO; Nunes FD; Carvalho MB; Tajara EH; Louro ID; Silva-Conforti AM
Genet Mol Res; 2015 Sep; 14(3):11145-53. PubMed ID: 26400345
[TBL] [Abstract][Full Text] [Related]
17. Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma.
Satchell AC; Barnetson RS; Halliday GM
Br J Dermatol; 2004 Jul; 151(1):42-9. PubMed ID: 15270871
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma.
Loro LL; Vintermyr OK; Johannessen AC; Liavaag PG; Jonsson R
J Oral Pathol Med; 1999 Feb; 28(2):82-7. PubMed ID: 9950255
[TBL] [Abstract][Full Text] [Related]
19. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
[TBL] [Abstract][Full Text] [Related]
20. The distribution and intracellular location of Fas and Fas Ligand following gastric carcinogenesis: Fas Ligand expressing gastric carcinoma cells can inhibit local immune response.
Liu H; Ubukata H; Tabuchi T; Nakachi T; Nagata H; Shimazaki J; Motohashi G; Konishi S; Nishimura M; Satani T; Hong J; Nakada I; Saniabadi AR; Tabuchi T
Mol Cell Biochem; 2009 Nov; 331(1-2):181-6. PubMed ID: 19458913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
